BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17325855)

  • 21. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.
    Masuyama J; Murakami T; Iwamoto S; Fujita S
    Cytotherapy; 2016 Jan; 18(1):80-90. PubMed ID: 26549384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
    von Kutzleben S; Pryce G; Giovannoni G; Baker D
    Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
    Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
    Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
    Siders WM; Shields J; Garron C; Hu Y; Boutin P; Shankara S; Weber W; Roberts B; Kaplan JM
    Leuk Lymphoma; 2010 Jul; 51(7):1293-304. PubMed ID: 20377308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
    Dunleavy K; Wilson WH
    Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
    [No Abstract]   [Full Text] [Related]  

  • 26. Quantitative evaluation of CD52 expression in B-cell chronic lymphocytic leukemia.
    D'Arena G; Vigliotti ML; Matera R; Musto C; Iodice G; Tartarone A; Di Renzo N
    Leuk Lymphoma; 2003 Jul; 44(7):1255-7. PubMed ID: 12916884
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression and prognostic significance of platelet-derived growth factor receptor alpha in mature T- and natural killer-cell lymphomas.
    Chen YP; Chang KC; Su WC; Chen TY
    Ann Hematol; 2008 Dec; 87(12):985-90. PubMed ID: 18633616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinicopathologic study of 963 cases of mature T-cell and natural killer/T-cell lymphoma with respect to 2008 WHO classification of lymphoid neoplasms].
    Liang Q; Ye ZY; Su ZL; Lin HL; Shao CK; Lin SX; Rao HL; Mei KY; Zhao T; Liu YH; Luo DL; Zhu MG; Chen SH; Lin TY
    Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):291-5. PubMed ID: 20654150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis.
    Lim ST; Hee SW; Quek R; Lim LC; Yap SP; Loong EL; Sng I; Tan LH; Ang MK; Ngeow J; Tham CK; Ngo L; Tan MH; Tao M
    Eur J Haematol; 2008 Jan; 80(1):55-60. PubMed ID: 18028433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intestinal T-cell and natural killer-cell lymphomas in Taiwan with special emphasis on 2 distinct cellular types: natural killer-like cytotoxic T cell and true natural killer cell.
    Tung CL; Hsieh PP; Chang JH; Chen RS; Chen YJ; Wang JS
    Hum Pathol; 2008 Jul; 39(7):1018-25. PubMed ID: 18482744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD52 antigen may be a therapeutic target for eosinophilic rhinosinusitis.
    Zhang PL; Pennington JR; Prichard JW; Blasick TM; Brown AM; Potdar S
    Ann Clin Lab Sci; 2007; 37(2):148-51. PubMed ID: 17522370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of CD52 mRNA in the rat embryo.
    Ermini L; Aldi S; Rosati F
    Dev Growth Differ; 2008 Sep; 50(7):577-83. PubMed ID: 19238728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
    Golay J; Cortiana C; Manganini M; Cazzaniga G; Salvi A; Spinelli O; Bassan R; Barbui T; Biondi A; Rambaldi A; Introna M
    Haematologica; 2006 Mar; 91(3):322-30. PubMed ID: 16531255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
    Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
    Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas.
    Choe YS; Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Do YR; Kwon KY; Song HS; Lee MH; Park TI
    Leuk Lymphoma; 2006 Feb; 47(2):267-70. PubMed ID: 16321856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
    Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
    Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
    Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified.
    Ishida T; Inagaki H; Utsunomiya A; Takatsuka Y; Komatsu H; Iida S; Takeuchi G; Eimoto T; Nakamura S; Ueda R
    Clin Cancer Res; 2004 Aug; 10(16):5494-500. PubMed ID: 15328188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NK-cell lymphoma with nodal presentation and expression of cutaneous lymphocyte-associated antigen.
    Chang ST; Liao YL; Lin SH; Chuang SS
    Pathol Res Pract; 2010 Jul; 206(7):463-6. PubMed ID: 19628338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.